GENEVA--(BUSINESS WIRE)--GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical institution focused connected stopping causal factors driving the progression of neurodegenerative and autoimmune diseases specified arsenic aggregate sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID oregon post-COVID), contiguous announced the recruitment of archetypal patients successful its Phase 2 proceedings evaluating temelimab against long-COVID astatine the Geneva University Hospitals post-COVID session (lead centre), arsenic good arsenic successful each the different Swiss objective centres participating to the study, i.e., Inselspital successful Bern, REHAB Basel, Kantonsspital Graubünden successful Chur and the Centre Hospitalier du Valais Romand successful Sion (for much information, delight notation to objective trials.gov oregon to GeNeuro’s web site).
About GeNeuro
GeNeuro‘s ngo is to make harmless and effectual treatments against neurological disorders and autoimmune diseases, specified arsenic aggregate sclerosis, by neutralizing causal factors encoded by quality endogenous retroviruses (HERVs), which correspond 8% of quality DNA.
GeNeuro is based successful Geneva, Switzerland and has R&D facilities successful Lyon, France. It has rights to 17 patent families protecting its technology.
For much information, visit: www.geneuro.com
English (US)